Nuevolution in collaboration to develop drugs for epigenetic disorders

21 Oct 2010

Your browser does not support inline frames or is currently configured not to display inline frames. Copenhagen-based Nuevolution is collaborating with EpiTherapeutics, ExpreS2ion Biotechnologies and the Biotech Research & Innovation Centre (BRIC), University of Copenhagen, to identify and develop novel small molecule drugs against epigenetic factors.

The DKK24M budget project is supported by the Danish High Technology Fund.

In the collaboration, Nuevolution will apply its proprietary and powerful Chemetics technology to screen hundreds of millions small molecules. All biology and disease skills and expertises needed for the project to be successful are provided by EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (BRIC).

“We are delighted with the establishment of this collaboration. We believe that this consortium of skills represents the ideal combination to efficiently identify and develop novel drug leads toward epigenetic based disorders,” said Alex Gouliaev, CEO of Nuevolution A/S. “It is with great pleasure we apply our Chemetics technology within the exciting area of epigenetics and we are looking forward to a successful collaboration”.